News
Epredia and Mindpeak Announce EU Distribution Agreement for AI-Powered Image Recognition in Cancer Diagnostics
Epredia will add Mindpeak AI modules for pathology to its digital pathology portfolio, offering
enhanced precision and speed in diagnostic image review
RUNCORN, United Kingdom – February 24, 2026 – Epredia, a global leader in precision cancer
diagnostics and a subsidiary of PHC Holdings Corporation (TSE: 6523), and Mindpeak, a leading
provider of artificial intelligence (AI) solutions for clinical and research pathology, today announced a
distribution agreement to bring Mindpeak’s AI-based image recognition software to Epredia’s digital
pathology customers in the European Union.
As cancer cases increase and diagnostic processes become more complex, pathology laboratories
are under pressure to speed up processes and reduce costs. Mindpeak’s AI technology delivers
instant, pixel-level analysis of digital images of tissue samples, enabling objective and reproducible
assessments in breast cancer, lung cancer, gastrointestinal pathology, biomarker quantification and
exploratory research studies. These tools are designed to reduce variability, support decision-
making and improve workflow efficiency, all without requiring cloud connectivity, thereby offering
data privacy and security for both clinical and research environments. Mindpeak’s AI portfolio
includes a range of both CE Marked and research-use-only modules.
Under the agreement, Epredia will offer Mindpeak’s AI software for clinical diagnostics, translational
research, and pharmaceutical development. In the future, Epredia also intends to explore integration
of Mindpeak’s AI solutions into the Epredia E1000 Dx Digital Pathology Solution workflow, which
would enable a seamless workflow and streamlined data exchange through Epredia’s image
management system. The E1000 Dx consists of a high-speed, automated, whole-slide imaging
digital scanner with medical grade viewer and advanced image management and viewer software
that allows review of up to 1,500 high-resolution digital images daily.
“Epredia is committed to providing the right tool at the right time to help pathology labs deliver
accurate, efficient diagnoses of cancer, so patients can get the care they need,” said Steven Lynum,
President of Epredia. “Our entire workflow of solutions, from stains to digital scanners, works
together to create the high-quality tissue samples needed for diagnosis, and AI image recognition
software has the potential to bring a new level of speed, accuracy, and reliability to that process.”
“Working with Epredia strengthens our shared mission to bring reliable, real-time AI support into the
hands of pathologists everywhere,” said Felix Faber, Co-founder and CEO of Mindpeak. “Together
we can help laboratories achieve faster, more consistent image interpretation and move closer to
scalable, expert-directed cancer diagnostics.”
This agreement will expand Epredia’s portfolio of end-to-end pathology solutions that includes
pathology consumables like slides and stains, instruments from tissue processors to cryostats, and
advanced image management systems including AI-enabled tools.
About Epredia
Epredia is a global leader in the anatomical pathology field, providing comprehensive solutions for
precision cancer diagnostics and tissue diagnostics. Powered by key brands, including Erie
Scientific, Menzel-Gläser, Microm, Shandon, and Richard-Allan Scientific, Epredia’s portfolio
includes microscope slides, instruments and consumables. Epredia was established following the
acquisition of Thermo Fisher Scientific’s Anatomical Pathology business by PHC Holdings (TSE
6523) in 2019. Epredia has manufacturing sites in the United States, the United Kingdom, Italy,
France, and China with a total of around 1,200 employees. Epredia is committed to achieving its
mission to improve lives by enhancing cancer diagnostics for patients around the world. For further
About PHC Holdings Corporation (PHC Group)
PHC Holdings Corporation (TSE 6523) is a global collection of healthcare companies with a mission
of contributing to the health of society through healthcare solutions that have a positive impact and
improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC
Corporation, Ascensia Diabetes Care, Epredia, LSI Medience Corporation, Wemex Corporation and
Mediford Corporation. Together, these companies develop, manufacture, sell and service solutions
across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group’s
consolidated net sales in FY2024 were JPY 361.6 billion with global distribution of products and
About Mindpeak
Founded in 2018, Mindpeak is a global innovator in AI-driven digital pathology solutions. The
company develops cutting-edge algorithms that support pathologists in routine diagnostics, focusing
on automating tissue analysis for faster, more accurate results. Mindpeak’s platform is designed to
enhance productivity and diagnostic confidence in clinical labs, helping to improve patient outcomes
For more information, please contact:
Julia Cottrill
PHC Group Corporate Communications
Email: julia.cottrill@phchd.com